IE
LXEO icon

Israel Englander’s Lexeo Therapeutics LXEO Stock Holding History

Israel Englander’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.2M Buy
2,833,622
+1,220,842
+76% +$6.6M ﹤0.01% 2013
2026
Q1 		$9.26M Buy
1,612,780
+704,756
+78% +$4.99M ﹤0.01% 2246
2025
Q4 		$9.02M Sell
908,024
-1,405,618
-61% -$12.8M ﹤0.01% 2374
2025
Q3 		$15.4M Sell
2,313,642
-522,650
-18% -$2.53M 0.01% 1954
2025
Q2 		$11.4M Buy
2,836,292
+1,764,803
+165% +$5.8M 0.01% 2127
2025
Q1 		$3.72M Buy
1,071,489
+929,538
+655% +$4.12M ﹤0.01% 3161
2024
Q4 		$934K Buy
141,951
+104,837
+282% +$826K ﹤0.01% 4258
2024
Q3 		$336K Sell
37,114
-352
-0.9% -$4.2K ﹤0.01% 5124
2024
Q2 		$601K Sell
37,466
-556,256
-94% -$8.08M ﹤0.01% 4474
2024
Q1 		$8.73M Buy
593,722
+549,622
+1,246% +$8.6M ﹤0.01% 2322
2023
Q4 		$592K Buy
+44,100
New +$548K ﹤0.01% 4537

Other funds holding LXEO

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Israel Englander's LXEO Position: Q2 2026 in Review

Israel Englander increased its Lexeo Therapeutics (LXEO) stake by 76% in Q2 2026, buying an estimated $6.6M and bringing the position to 2,833,622 shares worth $13.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2013.

Israel Englander first reported a position in LXEO in Q4 2023 and has held it in 11 quarters since. The position peaked at $15.4M in Q3 2025. 142 funds tracked by Wall St. Rank hold LXEO as of Q2 2026.

  • Israel Englander held 2,833,622 shares of Lexeo Therapeutics worth $13.2M as of Q2 2026.
  • Israel Englander bought 1,220,842 Lexeo Therapeutics shares in Q2 2026, an estimated $6.6M.
  • Lexeo Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2013 holding.
  • Israel Englander first reported a position in Lexeo Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Israel Englander's Lexeo Therapeutics position peaked at $15.4M in Q3 2025.
  • 142 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.